A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results
@article{Coronel2011ADP, title={A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results}, author={J. Coronel and L. Cetina and I. Pacheco and C. Trejo-Becerril and A. Gonz{\'a}lez-Fierro and E. De la Cruz-Hernandez and E. P{\'e}rez-C{\'a}rdenas and L. Taja-Chayeb and Daymi Arias-Bofill and M. Candelaria and S. Vidal and A. Duenas-Gonzalez}, journal={Medical Oncology}, year={2011}, volume={28}, pages={540-546} }
The reversing of epigenetic aberrations using the inhibitors of DNA methylation and histone deacetylases may have therapeutic value in cervical cancer. This is a randomized phase III, placebo-controlled study of hydralazine and valproate (HV) added to cisplatin topotecan in advanced cervical cancer. Patients received hydralazine at 182 mg for rapid, or 83 mg for slow acetylators, and valproate at 30 mg/kg, beginning a week before chemotherapy and continued until disease progression. Response… CONTINUE READING
104 Citations
New molecular targets against cervical cancer
- Medicine
- International journal of women's health
- 2014
- 36
- PDF
Hydralazine–valproate: a repositioned drug combination for the epigenetic therapy of cancer
- Medicine
- Expert opinion on drug metabolism & toxicology
- 2014
- 41
Clinical and biological effects of demethylating agents on solid tumours - A systematic review.
- Medicine
- Cancer treatment reviews
- 2017
- 46
Developments in the systemic treatment of metastatic cervical cancer.
- Medicine
- Cancer treatment reviews
- 2013
- 37
Epigenetic treatment of solid tumours: a review of clinical trials
- Biology, Medicine
- Clinical Epigenetics
- 2015
- 132
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
- Medicine
- International Journal of Gynecologic Cancer
- 2017
- 25
Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
- Chemistry, Medicine
- International journal of clinical pharmacology and therapeutics
- 2011
- 14
References
SHOWING 1-10 OF 45 REFERENCES
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
- Medicine
- BMC Cancer
- 2007
- 96
A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
- Medicine
- PloS one
- 2006
- 126
- PDF
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
- Biology, Medicine
- Clinical Cancer Research
- 2009
- 134
- PDF
Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers
- Biology, Medicine
- Clinical Cancer Research
- 2008
- 150
- PDF
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2007
- 206
A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors
- Medicine
- Clinical Cancer Research
- 2009
- 69
- PDF
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
- Medicine
- Clinical Cancer Research
- 2009
- 94
- PDF
Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas
- Biology, Medicine
- Clinical Cancer Research
- 2009
- 111
- PDF
Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
- Biology, Medicine
- Clinical Cancer Research
- 2009
- 80
- PDF
Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma
- Medicine
- Clinical Cancer Research
- 2006
- 134
- PDF